Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $33,438.96
0% from low
Exchange
OTC Link
CS
Borrow rate
79.88%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $105.0K | $933.7K | $645.2K | $134.0K | $3.2K |
| Cost of revenue | $0 | $0 | $17.8K | $78.0K | $766.8K | $756.8K | $627.5K | $2.9K |
| Gross profit | $0 | $0 | −$17.8K | $27.1K | $166.9K | −$111.7K | −$493.0K | $268 |
| Gross margin | — | — | — | 25.8% | 17.9% | -17.3% | -368.0% | 8.4% |
| R&D | $525.0K | $175.4K | $938.0K | $5.0M | $7.3M | $7.1M | $10.9M | $3.2M |
| Operating income | −$5.6M | −$5.9M | −$8.9M | −$41.9M | −$25.5M | −$26.1M | −$27.9M | −$19.6M |
| EBITDA | $0 | $45.0K | −$8.8M | −$44.0M | −$24.8M | −$25.5M | −$27.0M | −$40.1M |
| Net income | −$5.7M | −$5.8M | −$9.1M | −$46.4M | −$27.6M | −$32.4M | −$34.4M | −$41.7M |
| Net margin | — | — | — | -44148.6% | -2961.3% | -5018.9% | -25708.8% | -1305608.8% |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3062.42 | -1153.83 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-22828802400.00 | $-22828802400.00–$-22828802400.00 | 1 |
| 2027 | $1M | $-23216889600.00 | $-23216889600.00–$-23216889600.00 | 1 |
| 2028 | $1M | $-96.73 | $-96.73–$-96.73 | 1 |
Forward consensus · source: Financial Modeling Prep
ADITXT INC
No one on the platform currently holds ADTX.
No tracked institution reports a position in ADTX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-05-18 | 1-for-27reverse |
| 2026-03-09 | 1-for-8reverse |
| 2025-11-03 | 1-for-113reverse |
| 2025-03-17 | 1-for-250reverse |
| 2024-10-02 | 1-for-40reverse |
No one on the platform has traded ADTX yet.
| $27M |
| — |
| BLRXBioLineRx Ltd. | $3.10 | -2.05% | $13M | — |
| CTXRCitius Pharmaceuticals, Inc. | $0.58 | +7.15% | $6M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ADTX The $150 million is an estimated valuation of Ignite for the spinoff/merger. It's not profit. Even the hearings panel thought that valuation was BS. Ignite has already failed to provide financial results to Copley on time. This is a big red flag that they have no intention to pursue the deal.
View on StockTwits ↗$ADTX Why would ADTX want to risk losing 115 M dollars profit from a 35M investment by being noncompliant with Nasdaq? Regulatory & Approvals: The proposed business combination still requires approval from shareholders and regulators, as well as satisfaction of minimum cash or financing conditions Aditxt Signs Agreement to Spin Out Ignite Proteomics in $150 Million Public Market Transaction.Aditxt's Financial Health: Aditxt guaranteed certain obligations of Ignite under the combination agreement Copley to Merge With Ignite Proteomics in $150 Million Stock Deal. If Aditxt's delisting process triggers severe operational disruptions or liquidity issues, it could impact the closing of the deal.
View on StockTwits ↗$ADTX I'm not leaving. Parked here holding these bags of gold.
View on StockTwits ↗$ADTX A lot of people have left the chat and more will leave soon ! Bears have a pattern of hyping everyone with a fake pump and dump it for a while for about 2-3 years then you’ll look at this chat and almost everyone will be gone! But then I be around taking a pick !
View on StockTwits ↗$ADTX the interim CEO and many know nasdaq delisting was a done deal and no need to appeal. This is for the money. Making money is was this is about.
View on StockTwits ↗$ADTX Seems to be alot of fussing about adtx becoming nasdaq compliant........ that ia not needed for the ignite deal to go through.... let them dilute aNd take it to .0001
View on StockTwits ↗$ADTX an interim CEO is not an official ceo and has no authority to do anything on behalf of the company like signing binding contracts . A ceo has lots of power and right two positions are vacant for a reason . The company being hijacked by some unknown person who probably shorted the stock and made millions in profit. And he/she doesn't even own any shares of the company
View on StockTwits ↗$ADTX is a holding company. There is an interim CEO who will be the CEO for the merged company as well.
View on StockTwits ↗$ADTX Technically the company has no management no ceo, no chairman of the board, no chief financial officer, no legal counsel, no human resource manager, no directors, no investor relations, no head office for a reason . They don't want meet shareholders in person all of old management resigned. You can sue them if there is no employees. Does anyone know anybody in Richmond Virginia where there is an cop or FBI agent to do a wellness check on the corporation. Also I would like to volunteer to be ceo and chairman of the board. Anyone want to volunteer to all vacant positions in the company?
View on StockTwits ↗$ADTX They also need to prove positive equity of at least 2.5 M The company has until July 8, 2026 to file its appeal and pay the required review fee.
View on StockTwits ↗$ADTX Bottom line, this needs to get to $1.00 and the valuation of 15OM needs credible evidence in order for the appeal board to reverse the decision to suspend/ delist .
View on StockTwits ↗$ADTX Google AI raised these points: However, the future of the merger and ADTX stockholder benefits are highly uncertain…. Valuation Scrutiny: During the delisting review, the Nasdaq panel expressed skepticism regarding the sharp increase in Ignite Proteomics' valuation, which Aditxt had purchased for just $35 million only months before agreeing to the $150 million SPAC deal. Impact on the SPAC: The merger with Copley Acquisition Corp requires the ongoing participation, compliance, and strategic alignment of Aditxt as the parent entity. Status of the Appeal: While suspended, Aditxt has the option to request a review of the panel's decision, which could impact the timeline and execution of the merger.
View on StockTwits ↗$ADTX Did a Google Map Street View. Building NOT THERE.🤥 I'm calling BS, unfortunately. 😔
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.